CalciMedica is trading at $1.71, up 5.43%; no clear company-specific catalyst for the gain was found.

  • A September 30 prospectus supplement disclosed up to $25 million in common-stock sales through CalciMedica’s existing at-the-market offering agreement, a potential source of dilution. Available reporting does not establish that the filing caused the October 1 move.
  • Supplied major-index moves are modest and do not establish a broader-market explanation.